RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.» Read More
CNBC's Bertha Coombs discusses potential froth in the biotech sector due to an uptick in biotechnology IPOs.
FMHR traders Mike Murphy and Pete Najarian debate the play on the S&P biotech ETF.
Biotech firm Dendreon is set to begin selling its prostate cancer vaccine "Provenge" in Europe. John Johnson, Dendreon chairman & CEO, discusses the European launch and addresses investor concerns.
Sam Isaly of OrbiMed Advisors, explains why he likes the new products of Regeneron, and why he expects Intermune to go higher.
CNBC's Bertha Coombs reports on which sectors and stocks are impacted by Obamacare, and the FMHR traders share their top health care stock picks.
Barbara Ryan, FTI Consulting managing director, analyzes the biotech sector and reveals which companies are on the forefront of therapies worth investing in.
Steven St. Peter, Aratana Therapeutics president & CEO, discusses the need for pet medical pharmaceuticals and the market for pet insurance.
CNBC's Sheila Dharmarajan reports on what factors contribute to the biotech sector outperforming this year.
As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.
Mark Schoenebaum, ISI Group analyst, breaks down the red hot biotech sector and explains why Gilead Sciences is his best play.
Dan Fitzpatrick, StockmarketMentor.com president & technical analyst, takes a look at the charts to get a technical read on Twitter. Also a look at why Fitzpatrick likes the biotech sector.
Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss its firm's success, and how rising yields impact its dividend.
Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss real estate demand in the biotech industry.
Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.
Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.
Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.
The Supreme Court upheld Monsanto's biotech seed patents on Monday, dealing a blow to organic farmers and critics of the company.
The outlook for biotech is "wonderful," explains Sam Isaly, Orbimed Advisors managing partner.
Shares of Intercept Pharmaceuticals are up more than 560 percent this week alone. Akiva Felt, Oppenheimer senior analyst, shares his optimistic view for the company.
Daryl Liew, Head Of Portfolio Management of REYL Singapore advises investors to look past short-term volatilities in the country's economy after Q4 GDP data missed expectations